[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574449":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":19,"locations":28,"responsibleParty":53,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"CSDH patients",null,"All adult patients diagnosed with chronic subdural hematoma who provide informed consent to participate in the study will be included. Participants will receive standard care, with treatment determined by their treating physician based on clinical judgment. Treatment options may include burr hole drainage, craniotomy, embolization of the middle meningeal artery, pharmacological management, or a wait-and-scan approach. Follow-up will be conducted at 3 months via a telephone interview.",[13,16],{"name":14,"affiliation":5,"role":15},"Ruben Dammers","PRINCIPAL_INVESTIGATOR",{"name":17,"affiliation":18,"role":15},"Dagmar Verbaan","Amsterdam UMC",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Rahman Fakhry","CONTACT","+31 10 7043507","r.fakhry@erasmusmc.nl",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},"Dana C. Holl","d.holl@erasmusmc.nl",[29,42],{"facility":18,"status":30,"city":31,"state":10,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Amsterdam","Netherlands","NL",{"type":35,"coordinates":36},"Point",[37,38],4.88969,52.37403,{"lat":38,"lon":37},[41],{"name":17,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":43,"status":30,"city":44,"state":10,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Erasmus MC","Rotterdam",{"type":35,"coordinates":46},[47,48],4.47917,51.9225,{"lat":48,"lon":47},[51,52],{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"name":14,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":15,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"R. Dammers","Principal Investigator","100574449","registry-of-chronic-subdural-hematoma-100574449",false,"NCT06759428","Registry of Chronic Subdural Hematoma","CSDH Registry","Inclusion Criteria:\n\n* Patients diagnosed with CSDH\n* 18 years or older\n\nExclusion Criteria:\n\n* Patients who do not consent to participate in the registry","ALL","18 Years",{"count":66,"type":67},1500,"ESTIMATED","3 Months","OBSERVATIONAL","The goal of this observational study is to better understand how chronic subdural hematoma (CSDH) progresses and how patients are treated and cared for. The study focuses on three main questions:\n\n1. What are the characteristics of patients with CSDH when they are diagnosed?\n2. What treatments do patients with CSDH receive?\n3. What are the outcomes for patients with CSDH, including their functional ability, cognitive health, and neurological status?\n\nParticipants will receive their usual standard treatment. As part of the study, they will complete a brief telephone interview three months after their treatment.",[72,73],"Chronic Subdural Hematoma","Registry",[75,76,73,77,78,79],"Chronic subdural hematoma","Traumatic Brain Injury","Treatment outcome","Burr hole drainage","modified Rankin Scale","2025-01-06",{"date":82,"type":83},"2025-01-07","ACTUAL",{"date":85,"type":83},"2021-10-01",{"date":87,"type":67},"2028-01",{"name":5,"class":6},2]